Report Overview

The Infectious diseases drug market size in Kenya stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Infectious diseases continue to be the major causes of mortality in Kenya. Well known existing, emerging and re-emerging diseases like malaria, tuberculosis, HIV/AIDS, cholera, meningitis, hepatitis, schistosomiasis, lymphatic filariasis, Ebola and SARSare causing suffering and deaths in Kenya. Infectious Diseases are caused by wide range of micro-organisms like bacteria, viruses, fungi and parasites and can cause mild to severe illnesses or even death. According to UNAIDS report 2019, there are about 1.5 million adults and children living with HIV in Kenya. Though the prevalence rate has declined from 5.9% in 2018-19 to 4.8% in 2019-20, infection rates among young people remain concerning. In 2019, the Kenya national malaria incidence was reported at 125.92 cases per 1000 population. The WHO African region is home to 94% of malaria cases and deaths. Risk factors for infectious diseases include poor sanitation and personal hygiene. Despite increased government initiatives to control infectious diseases like malaria, HIV and tuberculosis and vaccination programmes, situation remains a cause of concern in Kenya.



Market Drivers

The market is majorly driven by the largest share of the Global Disease burden of Infectious diseases in Africa. Increasing initiatives taken by the Government of Kenya and Non-Governmental Organizations (NGOs) like distribution of free generic medicines in high incidence areas, increasing awareness among population to curb the spread of infectious diseases like HIV and tuberculosis will boost the market growth.

Furthermore, entry of generic drugs in market that are cost-effective is expected to increase the demand in infectious disease therapeutics.

Rising funding for research and development and development of new drugs will drive growth in the infectious diseases therapeutic market.

However, low penetration rate of anti-infectives and availability of large number of counterfeit drugs are expected to restrict growth in the market.